|
 |
Vincristine SulfateThis page contains recent news articles, when available, and an overview of Vincristine Sulfate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.In this study, researchers investigated Vincristine Sulfate Liposomes in specific patients with Philadelphia Chromosome-Negative Acute Lymphoblastic ... PR Newswire (press release) Hana Biosciences reports positive results from Phase II leukemia trial - Dec 10, 2009 ...adult population of ALL patients, with a universal history of prior exposure to the standard formulation of vincristine sulfate, said Hana. ... Trading Markets (press release) Esce a metà novembre un doppio di inediti e pezzi live dei BELLE & SEBASTIAN - Oct 21, 2009 The contribution of vincristine sulfate to this interaction is not certain. The interaction may result from reduced absorption of phenytoin and an increase ... ImpattoSonoro … Designation for Marqibo(R) (Vincristine Sulfate Liposomes Injection... - Jan 16, 2007 Orphan drug designation entitles Hana Biosciences to seven years of market exclusivity for Marqibo(R) (vincristine sulfate liposomes injection) in the ... Genetic Engineering News - Genetic Engineering News (press release) … Code - 77 Ill. Adm. Code 790.9530 VINCRISTINE SULFATE (Repealed) - Aug 10, 2005 77 Ill. Adm. Code 790.9530 VINCRISTINE SULFATE (Repealed) Repealed. (Source: Repealed at 17 Ill. Reg. 15916, effective September 20, 1993) ... Pay-Per-View - Illinois Administrative Code - Loislaw Chinese exporter suspected in tainted drugs scandal - Jan 31, 2008 ..."If they had been open about the vincristine sulfate in the beginning, maybe fewer people would have been harmed," she added. ... New York Times Film reviews: Gone Baby Gone and Mongol - Jun 7, 2008 In the presence of leukopenia or a complicating infection, administration of the next dose of vincristine sulfate injection warrants careful consideration. ... Telegraph.co.uk Press Release: INEX Presents Marqibo(TM) Clinical Data at Medical … - May 17, 2005 To participate in the conference call ... http://www.enzon.com/. About MARQIBO(TM) (vincristine sulfate liposomes ... ... Pay-Per-View - PR Newswire - HighBeam Research Hana Biosciences Completes Licensing of Three Targeted Cancer Drug … - May 8, 2006 Sphingosomal products, such as Marqibo(R) (vincristine sulfate) Liposomes Injection, are loaded with active, cell cycle-specific anticancer agents that may ... Free with registration - Business Wire - AccessMyLibrary.com New FDA Orphan Drugs: Droxidopa, LX201, Marqibo - Jan 30, 2007 Vincristine sulfate injection is approved by the FDA for the treatment of acute leukemia. It can also be used in combination with other oncolytic agents in ... Medscape Cancer Therapy; Reliability of preparation procedure for sphingosomal... - Oct 4, 2005 ..."All samples in both studies were evaluated by measuring key product characteristics, including free (unencapsulated) vincristine sulfate, total vincristine ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones VINCRISTINE (Intravenous route) - vin-KRIS-teen.(Drug overview) - May 1, 2007 Vincristine sulfate injection should be administered by individuals experienced in the administration of vincristine sulfate. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Tekmira's Partner Hana Biosciences Presents Marqibo ® Data at … - Dec 10, 2007 In an oral session on acute lymphoblastic leukemia therapy, Dr. Thomas presented publication #858, "Safety and Efficacy of Marqibo (Vincristine Sulfate ... marketwire.com HANA BIOSCIENCES GETS USORPHAN DRUG DESIGNATION FOR … - Aug 1, 2008 Upon FDA approval, orphan drug designation entitles Hana Biosciences to seven years of market exclusivity for Marqibo(r) (vincristine sulfate injection, ... Entrepreneur Trading Alert for Hana Biosciences Inc. - Jun 4, 2007 About Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) Marqibo, a novel, targeted, Optisomal formulation of vincristine, has shown promising ... Free with registration - M2 Presswire - AccessMyLibrary.com Article: HANA BIOSCIENCES REPORTS 2ND QTR 2005 NET LOSS OF $ … - Oct 1, 2005 Hana Biosciences has received ... Biotechnology, Cancer, Clinical Trial Research, Drug ... Vincristine Sulfate, Hana Biosciences Inc. This article ... ... Pay-Per-View - Biotech Financial Reports - HighBeam Research Press Release: Enzon Pharmaceuticals Terminates Marqibo Agreement. - … - Mar 17, 2005 Marqibo (vincristine sulfate liposomes injection). Marqibo is a proprietary drug comprised of the widely used off-patent anticancer drug vincristine ... Pay-Per-View - PR Newswire - HighBeam Research Getting the patient's mind off medicine at Packard's Children's... - Apr 9, 2006 Following surgery and radiation, she now comes in for weekly doses of vincristine sulfate, and chemotherapy every three weeks, all applied through a port in ... San Francisco Chronicle China recalls tainted leukemia drugs - Sep 16, 2007 It said the Health Ministry and drug administration had traced the problems with the drugs to their being tainted with vincristine sulfate, an anticancer ... USA Today Most problematic leukemia drugs recalled - Sep 16, 2007 14, the MOH and the SFDA said in a joint notice that investigations showed that the incidents happened because vincristine sulfate, an anti-cancer medicine, ... æ–°å?Žç½‘ FDA Moves Cancer Cures Into The Slow Lane - Jan 18, 2005 The debate turned on the FDA's consideration of Inex Pharmaceutical's application for accelerated approval of Marqibo vincristine sulfate liposome injection ... Forbes Contaminated leukemia drug victims to receive … - Dec 3, 2007 ...incidents happened because several batches of the two drugs had been contaminated by vincristine sulfate, an anti-cancer medicine, during production. ... æ–°å?Žç½‘ China Shuts Down Leukemia Drug Maker - Dec 13, 2007 The investigation found that the drugs were contaminated with vincristine sulfate — another cancer-fighting chemical — during production, the drug safety ... San Francisco Chronicle MAKER OF ABORTION PILL AT CENTER OF DRUG SCANDAL - - Feb 3, 2008 In September, health and drug officials announced that they had found the two drugs had been contaminated with vincristine sulfate, a third cancer drug, ... $2.95 - Pittsburgh Post-Gazette - NewsBank Fatal Misadministration of IV Vincristine - Jan 5, 2006 The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hospital Pharmacy 2001;36:740-745.) ... Medscape WHO expert committee on specifications for pharmaceutical preparations... - Aug 1, 2005 185125 9930435 trimethoprim 100mg 179093 9930440 vincristine sulfate 9.7mg/vial 193181 9930439 warfarin 100mg 168041 9930260 zuclomifene 50mg 187137 ... Free with registration - Technical Report Series - AccessMyLibrary.com Outbreak of Fusarium Keratitis in Soft Contact Lens Wearers in San … - Jun 12, 2006 ...lens wearer undergoing CHOP chemotherapy (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for non-Hodgkin lymphoma. ... Archives of Ophthalmology Tekmira Pharmaceuticals Releases 2007 Audited Operating Results - Mar 30, 2008 Initiation by Tekmira partner Hana Biosciences Inc. (NASDAQ:HNAB) of a Phase 2 clinical trial evaluating Marqibo ® (vincristine sulfate injection, ... marketwire.com Hana Biosciences Reports First Quarter 2006 Results - May 4, 2006 The three candidates are known as Marqibo(R) (vincristine sulfate) Liposomes Injection, Vinorelbine Liposomes Injection, and Topotecan Liposomes Injection. ... Genetic Engineering News - Genetic Engineering News (press release) Alabama Administrative Code - 540-X-4-.07 Emergency Prescription … - Aug 17, 2005 ...(VI) Dactinomycin (VII) Picamycin (vi) Mitotic Inhibitors (I) Etoposide (II) Vincristine Sulfate (III) Vinblastine Sulfate (vi) Radiopharmaceutical (I) ... Pay-Per-View - Alabama Administrative Code - Loislaw Hana Biosciences' Marqibo Receives Orphan Designation From … - Jul 14, 2008 ...medical product designation to Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) for the treatment of adult acute lymphoblastic leukemia (ALL). ... Lifescience-online Hana Biosciences Announces Third Quarter 2006 Results - Nov 2, 2006 Initiated a multicenter Phase II clinical trial of Marqibo(r) (vincristine sulfate liposomes injection) in patients with relapsed or refractory acute ... primezone.com Federal Register 2007 - 72 FR 62858 Lederle Laboratories et al.; … - Nov 7, 2007 ANDA 70-867 Vincrex (vincristine sulfate Bristol-Myers Squibb Co. for injection USP), ... Pay-Per-View - Federal Register 2007 - Loislaw Tekmira Pharmaceuticals Releases 2007 Audited Operating Results - Mar 31, 2008 Initiation by Tekmira partner Hana Biosciences Inc. (NASDAQ: HNAB) of a Phase 2 clinical trial evaluating Marqibo® (vincristine sulfate injection, ... Web Services Journal - Web Services Journal Hana Biosciences Announces Conference Call on Third Quarter 2006 … - Oct 26, 2006 The business update will include a review of Hana's pipeline including Zensana[TM] (Ondansetron HCI) Oral Spray and Marqibo[R] (vincristine sulfate ... Free with registration - Business Wire - AccessMyLibrary.com Alabama Administrative Code - 680-X-2-.26 Emergency Prescription … - Aug 17, 2005 ...(VI) Dactinomycin (VII) Plicamycin (vi) Mitotic Inhibitors (I) Etoposide (II) Vincristine Sulfate (III) Vinblastine Sulfate (vii) Radiopharmaceuticals ... Pay-Per-View - Alabama Administrative Code - Loislaw Hana Biosciences Initiates Marqibo(R) Phase II Clinical Trial in... - Aug 17, 2006 II clinical trial of Marqibo(R) (vincristine sulfate liposomes injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). ... RedOrbit Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response … - Sep 9, 2008 ...criteria to proceed to full enrollment of 56 patients has been achieved in its pivotal clinical trial of Marqibo(r) (vincristine sulfate injection, ... RedOrbit Hana Biosciences' Phase 2 Clinical Trial of Marqibo for Metastatic... - Jun 2, 2008 ...met in its Phase 2 clinical trial of Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) for the treatment of metastatic malignant uveal melanoma. ... RedOrbit Hana Biosciences licenses oncology drugs from Inex.(Inex … - May 15, 2006 The deal has doubled Hana's pipeline to six clinical-stage oncology compounds, including Marqibo (vincristine sulfate), which has shown promising results in ... Free with registration - Pharma Marketletter - AccessMyLibrary.com 2005 CPhI Show in Print Profile.(Chinese pharmaceutical industry) - Oct 26, 2005 Our company manufactures the following products: VINCRISTINE SULFATE CAS RN2068-78-2 VINBLASTINE SULFATE CAS RN: 143-67-9 VINORELBINE BITARTRATE CAS RN: ... $4.95 - Chemical Week - ECNext Federal Register 2007 - 72 FR 8184 Withdrawal of Approval of 128 … - Feb 23, 2007 CP1 ------------------------------------------------------------------------ 85P-0084/ Vincristine Sulfate 2 mg Bristol Laboratories CP1 ... Pay-Per-View - Federal Register 2007 - Loislaw License Revoked From Shanghai Hualian Pharmaceutical Factory - Jan 7, 2008 ...concerned departments in Shanghai identified the cause of the accident: Hualian's staff mixed Vincristine Sulfate into Methotrexate for injection and ... ChinaCSR.com FDA knocks back anticancer drug Marqibo - Jan 19, 2005 States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) ... News-Medical.net Hana Biosciences Initiates Marqibo(R) Phase 2 Clinical Trial in... - Aug 3, 2007 ...today announced the initiation of a multi-center, multi-national Phase 2 clinical trial of Marqibo([R]) (vincristine sulfate injection, OPTISOME[TM]) in ... Free with registration - Business Wire - AccessMyLibrary.com Other News To Note - Jul 14, 2008 Hana Biosciences, of South San Francisco, said the European Commission has granted orphan medical product designation to Marqibo (vincristine sulfate ... TMC Net Enzon and INEX Terminate Partnership - Mar 17, 2005 The partnership involves the development and commercialization of INEX's proprietary oncology product, MARQIBO (vincristine sulfate liposomes injection). ... WebProNews Acute Lymphoblastic Leukemia; Hana initiates Marqibo phase II trial... - Sep 12, 2006 ...phase II clinical trial of Marqibo (vincristine sulfate liposomes injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Hana Biosciences Reports Third Quarter 2008 Results - Nov 13, 2008 Marqibo(r) for adult acute lymphoblastic leukemia (ALL): Hana's registration-enabling Phase 2 rALLy pivotal clinical trial of Marqibo (vincristine sulfate ... RedOrbit Hana Biosciences Provides Pipeline Update - Mar 23, 2007 Marqibo(R) (vincristine sulfate liposomes injection) - Hana is no longer pursuing a Special Protocol Assessment (SPA) with the US Food and Drug ... Genetic Engineering News - Genetic Engineering News (press release) Other News To Note. - Dec 22, 2006 ...registration trial for Marqibo (vincristine sulfate liposomes injection) in adults with acute lymphoblastic leukemia (ALL) in second relapse and beyond. ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones Enzon Announces Termination of Agreements with INEX - Jan 7, 2005 ...partnership for the development and commercialization of INEX's proprietary oncology product, MARQIBO(R) (vincristine sulfate liposomes injection). ... businesswire.com Hana Biosciences Receives Fast Track Designation for Marqibo. - Aug 22, 2007 Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that Marqibo(r) (vincristine sulfate injection ... Free with registration - M2 Presswire - AccessMyLibrary.com Hana Biosci initiates Ph II Marqibo trial. - Aug 21, 2006 The USA's Hana Biosciences has initiated a multicenter Phase II clinical trial of Marqibo (vincristine sulfate liposomes injection) in patients with ... $9.94 - Pharma Marketletter - Alacra Store FDA Issues Not Approvable Letter for Marqibo - Jan 7, 2005 INEX Pharmaceuticals Corporation (TSX: IEX) detailing that the anticancer drug Marqibo(TM) (vincristine sulfate liposomes injection) is "not approvable" ... businesswire.com Tekmira Provides Update on Partners Clinical Progress - Nov 21, 2007 On November 20, 2007, Hana announced the initiation of a Phase 2 clinical trial of Marqibo(R) (vincristine sulfate injection, OPTISOME(TM)) in patients with ... Genetic Engineering News - Genetic Engineering News (press release) Approvals.(drug licenses)(Brief Article) - Feb 1, 2005 A "not-approvable" letter was issued for Enzon Phamaceuticals' Marqibo (vincristine sulfate liposomes injection) for relapsed aggressive non-Hodgkin's ... Free with registration - Biopharm International - AccessMyLibrary.com Tekmira Pharmaceuticals Provides Operational Update at AGM - Jun 20, 2007 ...the development and commercialization of three Tekmira products: Marqibo ® (vincristine sulfate liposomes injection), INX-0125 (Alocrest) and INX-0076. ... marketwire.com Tekmira Partner Hana Biosciences Achieves Clinical Progress in 2007 - Oct 23, 2007 ...and for product candidates Marqibo® (vincristine sulfate injection, OPTISOME(TM)), and Brakiva(TM) (topotecan hydrochloride injection, OPTISOME(TM)). ... Web Services Journal - Web Services Journal Hana Biosciences Initiates Marqibo Phase II Clinical Trial - Aug 6, 2007 Earlier this year, Marqibo (vincristine sulfate injection, Optisome) was granted orphan drug designation by the FDA for the treatment of adult ALL, ... FDA news - FDA news (subscription) Tekmira Pharmaceuticals Releases Third Quarter 2007 Operating Results - Nov 14, 2007 Initiation August 3, 2007 by Tekmira partner Hana Biosciences Inc. (NASDAQ:HNAB) of a Phase 2 clinical trial evaluating Marqibo ® (vincristine sulfate ... marketwire.com Orphan status for Hana's Marqibo.(Hana Biosciences gets approval)(Brie... - Jan 22, 2007 Orphan Drug designation for Marqibo (vincristine sulfate liposomes injection) in the treatment of adult patients with acute lymphoblastic leukemia. ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Hana Biosciences Initiates Marqibo Phase 2 Clinical Trial in Metastati... - Nov 20, 2007 ...in a Phase 2 clinical trial of Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) for the treatment of metastatic malignant uveal melanoma. ... Lifescience-online Hana Biosciences Receives Fast Track Designation for Marqibo - Aug 23, 2007 Earlier this year, Marqibo (vincristine sulfate injection, Optisome) was also granted orphan drug designation by the FDA for the treatment of adult ALL. ... FDA news - FDA news (subscription) Hana Biosciences to Present Data On Three Compounds At the AACR- … - Oct 9, 2007 Abstract #C111 -- "Vincristine sulfate liposomes injection concentrates vincristine in tumor tissue and bone marrow of tumor-bearing mice." ... Nanotechnology News - Nanotechnology News (press release) RealPennies.com : Turning Pennies into dollars: (PINKSHEETS: CNWI), (... - Aug 23, 2007 ...a biopharmaceutical company focused on advancing cancer care, today announced that Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) has received ... Free with registration - M2 Presswire - AccessMyLibrary.com Hana Biosciences Receives $30 Million Funding Commitment from … - Oct 31, 2007 The company is currently conducting a registration-enabling program for its lead compound, Marqibo([R]) (vincristine sulfate injection, OPTISOME[TM]), ... $4.95 - Business Wire - ECNext Non-Hodgkin Lymphoma; FDA issues "not approvable" letter for Marqibo - Feb 20, 2005 ...(IEX) detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Enzon Reports Third Quarter Results. - May 5, 2005 ...an agreement to terminate the companies' partnership for the development and commercialization of MARQIBO(R) (vincristine sulfate liposomes injection). ... $4.95 - Business Wire - ECNext INEX Pharmaceuticals Corp. Enzon announces termination of … - Apr 6, 2005 ...(IEX) to terminate the companies' partnership for the development and commercialization of INEX's proprietary oncology product, MARQIBO (vincristine sulfate ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Business Update; Enzon Pharmaceuticals terminates Marqibo agreement - Apr 19, 2005 Inc., (ENZN) to terminate the development and commercialization agreement for Marqibo (vincristine sulfate liposomes injection) effective immediately. ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Finance; Company attributes much of Q2's income drop to decline in … - Mar 22, 2005 This increase was primarily attributable to the company's share of costs related to MARQIBO (vincristine sulfate liposomes injection). ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Non-Hodgkin Lymphoma; FDA issues "not approvable" letter for Marqibo - Feb 14, 2005 ...(IEX) detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval ... Pay-Per-View - Clinical Trials Week - Factiva, from Dow Jones OTCPicks.com Stocks to Watch for Thursday, August 23rd GMEX, CHDO, … - Aug 23, 2007 Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, recently announced that Marqibo(r) (vincristine sulfate ... $4.95 - M2 Presswire - ECNext Press Release: Market Edge. - M2 Presswire | HighBeam Research: … - Aug 22, 2007 On Wednesday August 22nd Hana Biosciences announced that Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) has received Fast Track designation from ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Trading Alert for Hana Biosciences Inc. - M2 Presswire... - Jun 4, 2007 2007 announced the presentation of data for Menadione and Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) at the 43rd Annual American Society ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Hana Biosciences Inc. to Present Data on Two Programs.... - Jun 5, 2007 2007 announced the presentation of data for Menadione and Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) at the 43rd Annual American Society ... Pay-Per-View - M2 Presswire - HighBeam Research Business Update; Enzon announces termination of agreements - Apr 10, 2005 ...(IEX) to terminate the companies' partnership for the development and commercialization of INEX's proprietary oncology product, MARQIBO (vincristine sulfate ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Non-Hodgkin Lymphoma; FDA issues "not approvable" letter for Marqibo - Feb 15, 2005 ...(IEX) detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Finance; Company attributes much of Q2's income drop to decline in … - Mar 25, 2005 This increase was primarily attributable to the company's share of costs related to MARQIBO (vincristine sulfate liposomes injection). ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Business Update; Enzon Pharmaceuticals terminates Marqibo agreement - Apr 18, 2005 Inc., (ENZN) to terminate the development and commercialization agreement for Marqibo (vincristine sulfate liposomes injection) effective immediately. ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Approvals. - Feb 1, 2005 A "not-approvable" letter was issued for Enzon Phamaceuticals' Marqibo (vincristine sulfate liposomes injection) for relapsed aggressive non-Hodgkin's ... $9.94 - Biopharm International - Alacra Store Market Edge. - Aug 22, 2007 On Wednesday August 22nd Hana Biosciences announced that Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) has received Fast Track designation from ... $4.95 - M2 Presswire - ECNext Article: China Recalls Tainted Leukemia Drugs - AP Online | HighBeam ... - Sep 16, 2007 It said the Health Ministry and drug administration had traced the problems with the drugs to their being tainted with vincristine sulfate, an anticancer ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Press Release: Hana Biosciences Receives Fast Track Designation for … - Aug 22, 2007 Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that Marqibo(r) (vincristine sulfate injection ... Pay-Per-View - M2 Presswire - HighBeam Research Mayne Pharma (USA), Paramus, NJ, Feb. 1, (New Jersey).(Human Drugs … - Mar 1, 2005 Serious and unexpected ADE reports occurring with the use of morphine cytarabine, vincristine sulfate and methotrexate sodium were not submitted within 15 ... $4.95 - Warning Letter Bulletin - ECNext Press Release: FDA Issues Not Approvable Letter for Marqibo(TM). - PR... - Jan 19, 2005 ...letter detailing that the anticancer drug Marqibo(TM) (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval ... Pay-Per-View - PR Newswire - HighBeam Research China Recalls Tainted Leukemia Drugs | Article from AP Online | … - Sep 16, 2007 It said the Health Ministry and drug administration had traced the problems with the drugs to their being tainted with vincristine sulfate, an anticancer ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Article: China Recalls Tainted Leukemia Drugs - AP Online | HighBeam ... - Sep 16, 2007 It said the Health Ministry and drug administration had traced the problems with the drugs to their being tainted with vincristine sulfate, an anticancer ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Press Release: HNAB Up 36% After FDA Grants Fast Track for its … - Aug 22, 2007 ...a biopharmaceutical company focused on advancing cancer care, today announced that Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) has received ... Pay-Per-View - M2 Presswire - HighBeam Research 抗癌藥變毒藥ä¸åœ‹è—¥å» 掩蓋é?Žå¤± - Feb 2, 2008 ...èª¿æŸ¥è² è²¬äººå‘¨ç¾¤ï¼ˆZhou Qun，音è¯ï¼‰èªªï¼Œè—¥å» 沒有告訴調查員，硫酸長春新鹼（vincristine sulfate）ã€?一種é?žå¸¸æœ‰æ¯’çš„è—¥å“?，已å?Œå…¶ä»–藥物的原料一起被å˜æ”¾åœ¨å†°ç®±å…§ã€‚ ... epochtimes.com Ð’ Европе препарат Marqibo длÑ? лечениÑ? ОЛЛ получил «Ñ?иротÑ?кий» Ñ?Ñ‚ … - Jul 22, 2008 ЕвропейÑ?кой КомиÑ?Ñ?ией приÑ?воен «Ñ?иротÑ?кий» Ñ?татуÑ? инъекционному препарату Marqibo (vincristine sulfate) длÑ? лечениÑ? оÑ?трого лимфоблаÑ?тного лейкоза (ОЛЛ) у ... ФармацевтичеÑ?кий веÑ?тник КитайÑ?кие влаÑ?ти отозвали лицензию у производителÑ? препарат? - Dec 14, 2007 РаÑ?Ñ?ледование показало, что в препаратах methotrexate и cytarabin hydrochloride Ñ?одержалиÑ?ÑŒ чаÑ?тицы другого противоракового Ñ?редÑ?тва – vincristine sulfate. ФармацевтичеÑ?кий веÑ?тник |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |